Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1848 1
1873 1
1879 1
1958 1
1962 1
1963 1
1967 1
1968 2
1969 3
1970 2
1971 12
1972 3
1974 1
1975 1
1976 11
1977 13
1978 7
1979 4
1980 8
1981 5
1982 18
1983 25
1984 18
1985 20
1986 27
1987 23
1988 22
1989 16
1990 26
1991 10
1992 22
1993 27
1994 18
1995 28
1996 31
1997 49
1998 44
1999 55
2000 37
2001 34
2002 39
2003 46
2004 47
2005 56
2006 67
2007 86
2008 104
2009 100
2010 114
2011 124
2012 145
2013 169
2014 190
2015 207
2016 204
2017 196
2018 185
2019 207
2020 251
2021 303
2022 270
2023 247
2024 244
2025 261

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,980 results

Results by year

Filters applied: . Clear all
Page 1
Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses.
Laurie S, Steyaert W, de Boer E, Polavarapu K, Schuermans N, Sommer AK, Demidov G, Ellwanger K, Paramonov I, Thomas C, Aretz S, Baets J, Benetti E, Bullich G, Chinnery PF, Clayton-Smith J, Cohen E, Danis D, de Sainte Agathe JM, Denommé-Pichon AS, Diaz-Manera J, Efthymiou S, Faivre L, Fernandez-Callejo M, Freeberg M, Garcia-Pelaez J, Guillot-Noel L, Haack TB, Hanna M, Hengel H, Horvath R, Houlden H, Jackson A, Johansson L, Johari M, Kamsteeg EJ, Kellner M, Kleefstra T, Lacombe D, Lochmüller H, López-Martín E, Macaya A, Marcé-Grau A, Maver A, Morsy H, Muntoni F, Musacchia F, Nelson I, Nigro V, Olimpio C, Oliveira C, Paulasová Schwabová J, Pauly MG, Peterlin B, Peters S, Pfundt R, Piluso G, Piscia D, Posada M, Reich S, Renieri A, Ryba L, Šablauskas K, Savarese M, Schöls L, Schütz L, Steinke-Lange V, Stevanin G, Straub V, Sturm M, Swertz MA, Tartaglia M, Te Paske IBAW, Thompson R, Torella A, Trainor C, Udd B, Van de Vondel L, van de Warrenburg B, van Reeuwijk J, Vandrovcova J, Vitobello A, Vos J, Vyhnálková E, Wijngaard R, Wilke C, William D, Xu J, Yaldiz B, Zalatnai L, Zurek B; Solve-RD DITF-GENTURIS; Solve-RD DITF-ITHACA; Solve-RD DITF-EURO-NMD; Solve-RD DITF-RND; Solve-RD co… See abstract for full author list ➔ Laurie S, et al. Among authors: peters s. Nat Med. 2025 Feb;31(2):478-489. doi: 10.1038/s41591-024-03420-w. Epub 2025 Jan 17. Nat Med. 2025. PMID: 39825153 Free PMC article.
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
Peters S, Cho BC, Luft AV, Alatorre-Alexander J, Geater SL, Laktionov K, Trukhin D, Kim SW, Ursol GM, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Lowery C, Mann H, Stewart R, Jiang H, Garon EB, Mok T, Johnson ML. Peters S, et al. J Thorac Oncol. 2025 Jan;20(1):76-93. doi: 10.1016/j.jtho.2024.09.1381. Epub 2024 Sep 5. J Thorac Oncol. 2025. PMID: 39243945 Free article. Clinical Trial.
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Şendur MAN, Czyżewicz G, Caro RB, Lee KH, Johnson ML, Karadurmuş N, Grohé C, Baka S, Csőszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Paz-Ares L, et al. Among authors: peters s. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2. Lancet. 2025. PMID: 40473449 Clinical Trial.
Croup.
Peters S. Peters S. JAAPA. 2024 Apr 1;37(4):45-46. doi: 10.1097/01.JAA.0001007380.81031.21. Epub 2024 Mar 26. JAAPA. 2024. PMID: 38531033 No abstract available.
Targeting PIKfyve-driven lipid metabolism in pancreatic cancer.
Cheng C, Hu J, Mannan R, He T, Bhattacharyya R, Magnuson B, Wisniewski JP, Peters S, Karim SA, MacLean DJ, Karabürk H, Zhang L, Rossiter NJ, Zheng Y, Xiao L, Li C, Awad D, Mahapatra S, Bao Y, Zhang Y, Cao X, Wang Z, Mehra R, Morlacchi P, Sahai V, Pasca di Magliano M, Shah YM, Weisman LS, Morton JP, Ding K, Qiao Y, Lyssiotis CA, Chinnaiyan AM. Cheng C, et al. Among authors: peters s. Nature. 2025 Jun;642(8068):776-784. doi: 10.1038/s41586-025-08917-z. Epub 2025 Apr 23. Nature. 2025. PMID: 40269157 Free PMC article.
Le juste soin: entre audace thérapeutique et prudence clinique.
Addeo A, Herrera F, Tsoutsou P, Peters S. Addeo A, et al. Among authors: peters s. Rev Med Suisse. 2025 May 14;21(918):999-1000. doi: 10.53738/REVMED.2025.21.918.47348. Rev Med Suisse. 2025. PMID: 40369979 French. No abstract available.
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. Carbone DP, et al. Among authors: peters s. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493. N Engl J Med. 2017. PMID: 28636851 Free PMC article.
3,980 results